Progesterone News and Research RSS Feed - Progesterone News and Research

Bariatric surgery reduces uterine cancer risk by 71%

Bariatric surgery reduces uterine cancer risk by 71%

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center report that bariatric surgery resulting in dramatic weight loss in formerly severely obese women reduces the risk of endometrial (uterine) cancer by 71 percent and as much as 81 percent if normal weight is maintained after surgery. [More]
New theory regarding cause and development of endometriosis

New theory regarding cause and development of endometriosis

Changes to two previously unstudied genes are the centerpiece of a new theory regarding the cause and development of endometriosis, a chronic and painful disease affecting 1 in 10 women. [More]

Columbia Laboratories repurchases Actavis' block of shares at advantageous price

Columbia Laboratories, Inc. announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. [More]

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013. [More]
Study explores influence of reproductive, hormonal factors on overall survival of women with NSCLC

Study explores influence of reproductive, hormonal factors on overall survival of women with NSCLC

Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference. [More]
New research points to potential target for treating triple negative breast cancer

New research points to potential target for treating triple negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease. [More]

Findings may help doctors personalize preterm birth prevention treatments

New research findings may soon help doctors personalize preterm birth prevention treatments by identifying which women at higher risk for preterm birth will be helped by progesterone injections. [More]

Findings expand treatment options for hormone-dependent breast cancer

According to the United States Centers for Disease Control and Prevention, breast cancer is the most common cancer in women. For patients whose breast cancers are hormone-dependent, current treatment focuses on using drugs that block estrogen (a type of hormone) from attaching to estrogen receptors on tumor cells to prevent the cells from growing and spreading. [More]

Findings may help doctors personalize preterm birth prevention treatments

New research findings may soon help doctors personalize preterm birth prevention treatments by identifying which women at higher risk for preterm birth will be helped by progesterone injections. [More]
UCSF awarded grant of $2.7M for collaborative project aimed at reducing premature births

UCSF awarded grant of $2.7M for collaborative project aimed at reducing premature births

UC San Francisco has been awarded a Bill & Melinda Gates Foundation grant of $2.7 million over three years for a collaborative project aimed at reducing premature births. [More]

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years. [More]
New biomarker for stress in wild animals facing global climate change

New biomarker for stress in wild animals facing global climate change

Chemical analyses by neuroscientist Jerrold Meyer and colleagues at the University of Massachusetts Amherst are helping to establish hair cortisol concentration (HCC) as an important new biomarker for stress in wild animals facing global climate change. [More]
TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women. [More]
Protein may be major culprit when breast cancer metastasizes to the brain

Protein may be major culprit when breast cancer metastasizes to the brain

A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain. [More]
Molecule produced by brain acts as natural defence mechanism against cannabis

Molecule produced by brain acts as natural defence mechanism against cannabis

Two INSERM research teams led by Pier Vincenzo Piazza and Giovanni Marsicano (INSERM Unit 862 "Neurocentre Magendie" in Bordeaux) recently discovered that pregnenolone, a molecule produced by the brain, acts as a natural defence mechanism against the harmful effects of cannabis in animals. [More]

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial. [More]

Collaborative pharmaceutical project focusing on paediatric formulation development gets go-ahead

A collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant. [More]

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium. [More]
New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. [More]

Population Council partners with USAID to introduce new line of contraceptive rings

The Population Council was awarded a cooperative agreement from the U.S. Agency for International Development's Office of Population and Reproductive Health, "Delivering a Family of Contraceptive Vaginal Rings." Included in this agreement is support for two innovative, Population Council-developed contraceptive vaginal rings: a one-year contraceptive vaginal ring that can be used by women to plan their pregnancies and a three-month vaginal ring that can be used by breastfeeding women. [More]